Abstract
BackgroundTherapies which augment anti-cancer immune responses, such as immune checkpoint inhibitors (ICIs), have revolutionised cancer treatment in recent years. Despite inducing durable responses across different cancer types, not all patients...
Paper version not known (Free)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have